Medical device maker Boston Scientific beats Q3 revenue estimates on strong US demand

Boston Scientific

22/10/2025 11:40

Overview

Boston Scientific Q3 revenue grows 20.3%, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reaching $0.75

Company discontinues sales of ACURATE valve systems globally

Outlook

Boston Scientific estimates full-year 2025 net sales growth of ~20% reported, 15.5% organic

Company expects Q4 2025 net sales growth of 14.5%-16.5% reported, 11%-13% organic

Boston Scientific projects full-year 2025 GAAP EPS of $1.97-$2.01, adjusted EPS $3.02-$3.04

Result Drivers

CARDIOVASCULAR GROWTH - Cardiovascular segment reported a 22.4% increase in sales, driven by strong demand

U.S. MARKET STRENGTH - U.S. sales grew 27% on both reported and operational basis, leading regional performance

INNOVATION FOCUS - CEO attributes strong performance to category leadership strategy and innovation

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$5.06 bln
$4.96 bln (26 Analysts)
Q3 ADJUSTED EPS
Beat
$0.75
$0.71 (25 Analysts)
Q3 EPS
$0.51
Q3 Net Income
$755 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 35 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Boston Scientific Corp is $125.00, about 20.1% above its October 21 closing price of $99.90

The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 35 three months ago

Press Release: ID:nPn1k776ga

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)